Original document(9 pages)  中文版
    The present invention relates to entecavir granule as one hepatitis B treating medicine and its preparation process, and aims at providing one kind of entecavir granule preparation with the features of accurate dosage, stable quality, easy production and convenient carrying like other common solid preparation, and the features of easy swallow, high bioavailability, less stimulation on gastrointestinal tract, etc like orally taken liquid preparation. The entecavir granule is prepared with entecavir as main material and proper amount of medicine supplementary material and through a conventional technological process.
Application Number
申请号
200610152510 Application Date
申请日
2006.09.28
Title 名称 Entecavir granule and its prepn process
Publication Number
公开号
1931138 Publication Date
公开日
2007.03.21
Approval Pub. Date Granted Pub. Date
International Classification 分类号 A61K9/16;A61K31/513;A61P1/16;A61P31/12
Applicant(s) Name
申请人
Henan Furen Pharmaceutical Industry Co., Ltd.
Address 地址
Inventor(s) Name 发明人
Attorney & Agent 代理人
More information 更  多  信  息


 Related patents information
Orally taken liquid medicine composition containing strontium
Medicine composition for treating viral hepatitis and its prepn. method
Injection for treating bacterial inflammation injection and its preparation process
Injection for treating arthralgia due to wind-cold-dampness disease and its preparation process
Injection for treating upper respiratory tract infection and its preparation process
Entecavir effervescent tablet and its prepn process
Medicine composition for treating cardiac and cerebral vascular diseases and its prepn process
Medicine composition for treating leukopenia and its prepn process
Diterpene compound and derivative in kaurene class of new disymmetry
Traditional Chinese medicine mixture for treating AIDS stomatocace and recurrent stomatocace
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.